Kenneth Kintu

Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial

Kenneth Kintu, Thokozile R. Malaba, Jesca Nakibuka et al. · The Lancet HIV · 2020 · 117 citations · Full text

Treatment And Prevention, Dolutegravir Versus Efavirenz, Reproductive Health +11

Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)

Catriona Waitt, Catherine Orrell, Stephen Walimbwa et al. · PLoS Medicine · 2019 · 105 citations · Full text

Mentorship needs at academic institutions in resource-limited settings: a survey at makerere university college of health sciences

Damalie Nakanjako, Pauline Byakika‐Kibwika, Kenneth Kintu et al. · BMC Medical Education · 2011 · 59 citations · Full text

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study

Thokozile R. Malaba, Irene Nakatudde, Kenneth Kintu et al. · The Lancet HIV · 2022 · 50 citations · Full text

Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy

Bonus Makanani, Jennifer E. Balkus, Yuqing Jiao et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2018 · 33 citations